Following a year of solid growth in 2022, leading pharma company AstraZeneca’s (AZN) robust pipeline and recent launches look promising. Moreover, its strong fundamentals should enable the stock to deliver…
Following a year of solid growth in 2022, leading pharma company AstraZeneca’s (AZN) robust pipeline and recent launches look promising. Moreover, its strong fundamentals should enable the stock to deliver…